Key Takeaways, With Data for Maryland FDA approvals vary by drug: There are currently three GLP-1s on the market that the FDA ...

Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound and other anti-obesity drugs was third-highest in the ...

It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...

Wegovy is considered a safe and effective treatment for long-term weight loss. Possible problems with long-term use to discuss with your doctor include pancreatitis, gallbladder disease ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...